Amlonor

Quick links to important sections

Amlonor

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Amlonor

Amlonor is a trade name for the medicine whose active ingredient is Amlodipine. This compound is categorized as a Calcium Channel Blocker (CCB), a specific class of agent used in cardiovascular management. Amlodipine is a synthetic pharmaceutical substance, manufactured consistently to ensure reliable chemical structure and efficacy.


Quick Facts

Property Description
Active Ingredient Amlodipine (commonly as Amlodipine besylate)
Form Oral tablet or Oral liquid/suspension
Pharmacological Class Calcium Channel Blocker (Dihydropyridine type)
General Purpose To lower peripheral vascular resistance and reduce heart workload
Origin Synthetic

Amlonor: Definition and Core Pharmacological Identity

Amlonor is defined by its active constituent, Amlodipine, which belongs to the Dihydropyridine subclass of Calcium Channel Blockers (CCB). Amlodipine is effective at inhibiting the influx of calcium ions into vascular smooth muscle cells, establishing its core mechanism. This medicine's profile is clinically recognized for its long-acting duration, often sustaining its effects for 24 hours or more. This designation confirms the medicine's role in influencing vascular smooth muscle function to manage circulatory dynamics. Amlodipine differentiates itself as a long-acting peripheral arterial vasodilator, establishing its core identity as a key tool in systemic blood flow management. This medicine is strictly a prescription-only medication.

Composition and Available Pharmaceutical Forms

The core ingredient is Amlodipine, typically formulated as the stable salt Amlodipine besylate. The drug is most frequently supplied as an oral tablet, though specialized preparations, such as oral liquid or oral suspension, are also available, the latter being particularly relevant for patient groups requiring flexibility in administration. Regardless of the form, the active compound is combined with inert components (excipients) like microcrystalline cellulose and magnesium stearate to facilitate oral absorption. Amlodipine is used to treat both chronic stable and vasospastic forms of angina and hypertension. This means the medicine is generally recognized as effective for managing common cardiovascular conditions. Amlodipine is available both as a single-agent product (monotherapy) and is widely used in fixed-dose combination products with other antihypertensive agents to optimize therapeutic outcomes.

General Purpose and Therapeutic Classification

The general purpose of Amlonor is to reduce peripheral vascular resistance to consistently lower blood pressure. By acting as a peripheral arterial vasodilator, the medicine relaxes and widens the blood vessels. This effect directly decreases the systemic resistance that the heart must overcome, easing its workload. This fundamental therapeutic action is medically supported as a standard strategy for maintaining healthy arterial pressure. This action also improves blood flow to the cardiac muscle, which is generally helpful for mitigating the discomfort associated with restricted coronary blood supply, such as that experienced in chronic stable angina.

Regulatory References

  1. NIH/NCBI Bookshelf: Amlodipine - StatPearls
  2. EMA Norvasc (Amlodipine) Referral Information

What side effects are possible with Amlonor?

Possible Side Effects and Safety Information

The safety profile of Amlonor (Amlodipine) is defined by officially documented adverse reactions classified by frequency and grouped into System-Organ-Classes, based on regulatory standards such as those from the EMA and FDA. Most commonly reported adverse events relate to the medicine's vasodilatory action.

Frequency-Classified Adverse Reactions

Classification Common Examples
Very Common (ge 1/10) Peripheral edema (swelling), which is documented to be dose-dependent.
Common (ge 1/100 to < 1/10) Headache, dizziness, fatigue, flushing, palpitations, abdominal pain, and nausea.
Uncommon (ge 1/1,000 to < 1/100) Insomnia, tremor, syncope, hypotension, dyspnoea, dyspepsia, dry mouth, alopecia, and muscle cramps.

Serious adverse reactions, though classified as Rare or Very Rare, are explicitly noted in regulatory documents. These include myocardial infarction or worsening of angina that may occur upon initiation or increase of dosage, as well as severe, systemic reactions such as hepatitis, pancreatitis, and Severe Cutaneous Adverse Reactions (SCARs) like Stevens-Johnson syndrome.

Population-Specific Safety Notes

The regulatory labeling includes specific considerations for certain groups. Due to reduced clearance, individuals with hepatic impairment are often noted to require a lower initial dose. Similarly, elderly patients may experience increased plasma concentrations and often require cautious dosing. Safety and effectiveness are not established for pediatric patients under six years of age. Amlonor is generally contraindicated in cases of known hypersensitivity to the drug or other dihydropyridines, and in conditions like severe hypotension.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for an Amlonor (Amlodipine) overdose documents specific clinical manifestations and mandated emergency actions based on the drug's effect as a potent vasodilator.

Category Documented Regulatory Statement
Primary Manifestation Overdose is characterized by excessive peripheral vasodilation leading to marked and probably prolonged systemic hypotension.
Emergency Action Seek emergency medical attention or call the Poison Control Center immediately upon suspicion of overdose.

Clinically significant hypotension is the primary severe outcome noted in official labeling, requiring active cardiovascular support. The management procedures focus entirely on supportive and symptomatic treatment as described by regulatory authorities. These measures include the frequent monitoring of both cardiac and respiratory function, along with necessary attention to circulating fluid volume and urine output. A vasoconstrictor may be used as an official supportive step to help restore blood pressure, and procedures such as gastric lavage may be considered in some specific cases as part of the protocol.

Urgent medical help is strictly required if the individual has collapsed, experienced a seizure, has trouble breathing, or is unable to be awakened. These severe symptoms indicate the need for immediate contact with emergency services, as the management strategy is focused on mitigating the severe physiological consequences described in the prescribing information.

Therapeutic Uses of Amlonor

The primary therapeutic role of Amlonor (Amlodipine) is to provide supportive symptom management in therapeutic domains related to cardiovascular health, and it is commonly used across key areas of cardiovascular management.

The medicine is generally relevant for the long-term management of chronic, elevated arterial pressure (Hypertension) and recurring chest discomfort (chronic stable and vasospastic angina). This continuous stabilization helps support maintaining blood pressure within a managed range. Amlonor is generally used as a maintenance therapy and contributes to the management of symptoms related to heightened physiological activity. It helps reduce the frequency and severity of symptoms that interfere with daily comfort. This supports patients in maintaining a sense of stability and may assist with maintaining functional stability.


Quick Fact: Support for Systemic Pressure and Chest Discomfort
Primary Condition Sustained high blood pressure (Hypertension)
Symptom Domain Anginal chest pain, symptoms linked to organ-specific functional stress
Common Scenario Long-term daily management and prophylaxis of symptoms
Core Benefit Contributes to easing the overall symptom load and supports general well-being.

Regulatory References

  1. NIH DailyMed entry for Amlodipine besylate tablet

Eligibility and Restrictions for Use

Amlonor (Amlodipine) eligibility is strictly defined by regulatory authorities based on official contraindications and population-specific restrictions. The following outlines who is allowed or prohibited from using the medicine.

Populations Who Must Not Use Amlonor

Use is strictly contraindicated for individuals with a known hypersensitivity to amlodipine or to other medicines in the dihydropyridine class. It is also prohibited for patients experiencing severe hemodynamic instability, such as severe hypotension or any form of shock (including cardiogenic shock).

Age-Group Eligibility

The medicine is approved for adults for its labeled indications. For pediatric patients, Amlonor is indicated only for the treatment of hypertension in children aged 6 to 17 years. Safety and effectiveness have not been established for children younger than 6 years of age. Older adults may require a lower initial starting dose due to the potential for reduced organ function.

Conditional and Restricted Use

Eligibility is conditional for certain patient groups. Individuals with severe hepatic impairment require caution and slow dose titration due to impaired clearance. Use also requires clinical consideration for pregnant individuals and those who are lactating, as the drug passes into breast milk, and the mother is officially advised to consider discontinuing nursing or the medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Amlonor (Amlodipine) exhibits officially documented interaction patterns primarily through the CYP3A4 metabolic pathway and additive physiological effects. Co-administration with strong or moderate CYP3A4 inhibitors (such as certain antifungal or antiretroviral medicines) significantly increases Amlodipine’s systemic exposure, which raises the risk of hypotension as described in regulatory documents. Conversely, CYP3A4 inducers may alter plasma concentrations.

Formal restrictions exist for specific co-medications. The dose of Simvastatin must be limited to a maximum of 20 mg daily because Amlodipine substantially increases the systemic exposure of Simvastatin. Co-administration with Dantrolene (infusion) must be avoided due to the documented risk of hyperkalemia.

Additive effects are noted when Amlodipine is co-administered with other antihypertensive agents or Ethanol (Alcohol), which may reinforce the blood pressure lowering effect. Amlodipine may also increase the systemic exposure of the immunosuppressants Tacrolimus and Cyclosporine, necessitating monitoring as stated in the prescribing information.

Regarding substances, Grapefruit or Grapefruit Juice is not recommended as it may increase Amlodipine's bioavailability in some patients. For patients with hepatic impairment, decreased plasma clearance and a prolonged elimination half-life may heighten the magnitude of these interaction effects.

Mechanism of Action

How Amlonor Works

Amlonor's mechanism of action involves precise biological and physiological steps within the body. The overall process is centered on the targeted modulation of specific signaling cascades, which involves the adjustment of overactive physiological processes.

Primary Molecular Target and Action

Amlonor's effect begins with the modulation of defined receptor systems within cellular membranes. By initiating a specific molecular interaction, the compound acts to either initiate or suppress signaling events, which results in the rapid adjustment of target receptor or enzyme activity.

Downstream Pathway Modulation

Following the initial molecular binding, the drug operates by engaging in well-characterized intracellular signaling cascades. This activity alters the signal dynamics in defined humoral or neural pathways, which are often involved in contexts of heightened pathway activation.

Modulation of Overactive Processes

The cumulative mechanistic effect is to dampen excessive signaling and act to regulate overactive physiological responses. This targeted pathway interference contributes to modulating dysregulated physiological processes and affects the functional dynamics within the targeted biological systems.

Dosage and Administration Information

Administration Guidelines for Amlonor (Amlodipine)

Amlonor, which contains the active ingredient Amlodipine, is approved for oral administration and is intended for long-term daily use. The medicine must be taken once per day at a consistent time to maintain steady plasma levels. Administration is flexible and does not depend on mealtimes; the drug may be taken with or without food.


Standard Dosing Regimens and Adjustments

Parameter Guideline
Adult Starting Dose Typically 5 mg once daily. A lower initial dose of 2.5 mg once daily is used for older adults or patients with hepatic impairment.
Maximum Dose The maximum recommended daily dosage is 10 mg.
Titration Interval Dosage increases should proceed slowly, with an interval of 7 to 14 days between adjustments to allow for the full therapeutic effect to be assessed.

Procedural Rules for Specific Populations

The prescribed dosage for pediatric patients aged 6 to 17 years for hypertension ranges from 2.5 mg to 5 mg once daily, with 5 mg representing the maximum studied dose in this age group.

If a daily dose is missed, the dose should be taken as soon as it is remembered on the same day. However, if the time for the next scheduled dose is near, the missed dose should be skipped, and the regular schedule should be resumed. A double dose must not be taken to compensate for the missed administration. This framework ensures a standardized and predictable approach to long-term medication use.

Recent Clinical Evidence

Research evidence / Overview of Studies for Amlonor

Evidence for Use in Sustained High Blood Pressure (Hypertension)

Amlonor was evaluated in research exploring how the condition is managed. The evidence base includes many randomized controlled trials (RCTs), as well as broader reviews that pull together data from multiple studies. Research examined how Amlonor was associated with changes in blood pressure readings (systolic and diastolic) over defined time intervals. Studies monitored outcomes related to systemic or functional imbalance over several years, examining the rates of major events such as stroke or heart attack in the observed populations. Research describes findings related to achieving specific blood pressure goals, but these findings were mixed across the broad range of trials when comparing Amlonor against different control treatments studied.

Evidence for Use in Chronic Stable Angina

Amlonor was evaluated in trials assessing short-term or episodic symptom patterns in adults experiencing chronic stable angina. These studies primarily focused on outcomes reflecting daily functioning, specifically exploring measurements of how long participants could exercise on standardized tests before the onset of discomfort. Findings also indicate measurements related to the frequency of patient-reported outcomes describing perceived discomfort. However, the evidence is limited, as studies monitoring these responses typically had follow-up durations that were limited to weeks or months.

What Research Gaps and Uncertainties Remain

Studies help show what has been observed so far, but certain limitations mean that certainty remains low in several areas. Data for certain specific patient groups or those with multiple complex co-existing conditions remain insufficient. Study results reflect the specific conditions under which they were conducted and do not determine whether an individual will respond similarly. Long-term effects are not fully established, and data for the pediatric population (children aged 6 to 17) remain insufficient to establish full long-term outcomes.

Key Studies & References

  1. Effect of Amlodipine on the Progression of Atherosclerosis and the Occurrence of Clinical Events (PREVENT Investigators)

Frequently Asked Questions (FAQ)

Common questions about Amlonor (FAQ)

Q: Are there any dietary restrictions or foods to avoid while taking Amlonor?

Official product information notes that Grapefruit or Grapefruit Juice is not recommended due to the potential to affect how the drug works in the body. Regulatory documents also note that using Amlonor with Ethanol (Alcohol) may reinforce the drug’s blood pressure-lowering effect. There are no other general food-based restrictions noted in the official labeling.

Q: Is Amlonor considered safe to use during pregnancy according to official sources?

Official documents state that limited data from post-marketing reports are not sufficient to determine the specific drug-associated risk of adverse outcomes, such as birth defects or miscarriage. However, official labeling notes that there are known risks to mother and fetus associated with poorly controlled hypertension in pregnancy.

Q: How quickly does Amlonor leave the body after the last dose?

According to official pharmacological data, Amlodipine is eliminated over a terminal half-life of about 30 to 50 hours. This long duration reflects the medicine’s long-acting nature. Systemic plasma levels are usually reached after approximately one week of consecutive daily dosing.

Q: What should be done if an allergic reaction to Amlonor is suspected?

Amlodipine is contraindicated if a known hypersensitivity to the drug exists, and rare, severe systemic reactions are documented in the official labeling. Official labeling directs patients to report suspected adverse reactions to their healthcare provider.

Q: What is the success rate or overall patient satisfaction described in research for Amlonor?

Studies have demonstrated that Amlonor can lower blood pressure and improve exercise time for patients with angina. However, regulatory documents indicate that findings related to achieving specific blood pressure goals were mixed across trials when comparing Amlonor against different control treatments. The efficacy experienced by an individual patient may vary.

Q: Are there any long-term health risks associated with taking Amlonor for many years?

Long-term non-clinical studies in animals showed no evidence of causing cancer over a two-year period. Despite this, official patient documentation indicates that long-term outcome data for certain complex patient groups remain insufficient to fully establish all potential long-term effects.

Q: Can Amlonor change how other medicines are absorbed in the stomach?

The primary documented drug interactions occur because of the drug's metabolism through the CYP3A4 metabolic pathway, which is based in the liver. This process can significantly alter the systemic exposure (amount in the body) of certain co-administered drugs. Regulatory documents do not explicitly detail a mechanism for Amlonor’s impact on initial gastric absorption.

Q: Does Amlonor have a generic version available yet?

Yes, the active ingredient in Amlonor is Amlodipine Besylate. The FDA has approved multiple generic versions of Amlodipine Besylate tablets from various manufacturers.

Q: What kind of regular check-ups are needed while using Amlonor?

Official patient information notes that blood pressure monitoring is often required to determine the drug's effectiveness. Additionally, warnings for specific populations, such as those with hepatic (liver) impairment, imply the need for ongoing clinical supervision and monitoring.

Q: Can Amlonor affect a person's ability to drive or use machinery?

Regulatory documents list common adverse reactions that include dizziness, fatigue, and somnolence (drowsiness). These effects, if experienced by the patient, may affect their ability to drive or safely operate machinery.

Q: Do people gain weight while taking Amlonor?

Unusual weight changes, including weight gain or loss, have been reported during post-marketing experience. It is also important to note that the common side effect of edema (swelling) may be perceived as weight gain.

Q: Is Amlonor safe for people who have kidney problems?

According to official pharmacokinetic studies, the way Amlodipine works in the body is not significantly influenced by renal (kidney) impairment. Official labeling indicates that Amlodipine is often initiated at the usual dose for patients with renal impairment, as pharmacokinetics are not significantly influenced by kidney function.

Q: What happens if you suddenly stop taking Amlonor without tapering?

Official warnings note that worsening angina and acute myocardial infarction (heart attack) can develop in some patients after starting or increasing the dose. This information underscores the potential risks associated with any sudden change in regimen.

Q: Are there any known interactions with herbal supplements and Amlonor?

Regulatory documents note that the herbal supplement St John's wort is known to affect how Amlodipine works in the body. While most common vitamins and supplements are not formally listed, those that affect the CYP3A4 metabolic pathway (a liver enzyme system) may alter Amlodipine's systemic exposure.

Q: Is it okay to drink coffee or caffeine while taking Amlonor?

Caffeine is not a formally listed drug interaction in the official Amlodipine label. However, as a central nervous system (CNS) stimulant, caffeine can increase blood pressure and heart rate, which may potentially counteract the blood pressure lowering effect of Amlonor if consumed in high quantities.

Q: Is Amlonor generally considered a first-line treatment?

Official regulatory documentation indicates that Amlodipine is approved for the treatment of hypertension to lower blood pressure. It is specified that the medicine may be used alone or in combination with other antihypertensive agents.

Q: Can Amlonor interact with over-the-counter pain relievers?

Official drug interaction information notes that Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which include certain over-the-counter pain relievers, can interact with Amlodipine. This interaction may potentially lead to a loss of the anti-hypertensive effect, and clinical monitoring is often considered when these medications are taken together.

Q: What happens in the body when Amlonor starts to wear off?

Official labeling indicates the drug is characterized as long-acting, with antihypertensive effectiveness maintained for at least 24 hours with once-daily administration. After the last dose, the drug is gradually eliminated over a prolonged period, with a half-life of 30 to 50 hours.

Q: Does Amlonor cause feelings of anxiety or restlessness?

Psychiatric side effects, including mood changes (including anxiety) and nervousness, have been reported as uncommon or less frequent in official documentation from clinical trials.

Q: Is Amlonor a controlled substance?

According to official regulatory agencies, Amlodipine is not classified as a controlled substance and has no schedule classification under the Controlled Substances Act (CSA).

How should Amlonor be stored and disposed of?

Amlonor (amlodipine besylate) tablets must be stored at a Controlled Room Temperature, specifically defined as 20 C to 25 C (68 F to 77 F). Brief temperature excursions are permitted between 15 C and 30 C.

The medicine requires protection from environmental factors: it must be stored in its original, tightly closed, light-resistant container and must not be frozen or exposed to excess moisture. For safety, the product must be kept strictly out of the sight and reach of children.

Disposal of any unused or expired Amlonor must follow official local regulations for pharmaceutical waste. It is mandatory not to dispose of the product by flushing it down a toilet or pouring it into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Amlonor found in:

A-Z Index: